Riferimenti bibliografici
1. Bellentani S, Tiribelli C. The spectrum of liver disease in the general population: lesson from the Dionysos study. J Hepatol 2001; 35:531-7.
2. Gaeta GB, Stornaiuolo G, Precone DF, et al. Epidemiological and clinical burden of chronic hepatitis B virus/hepatitis C virus infection. A multicenter Italian study J Hepatol 2003; 39:1036-41.
3. Scotto G, Martinelli D, Di Tullio R, et al. Epidemiological and Clinical Features of Hepatitis B Virus Genotypes among Immigrants in Southern Italy. Hepat Res Treat. 2010; 2010:878356. Epub 2010 Apr 22.
4. Giusti G, Galanti B, Gaeta GB, et al. Clinical presentation and natural history of chronic persistent hepatitis. A multicenter retrospective study on 1197 cases. Ital J Gastroenterol 1991; 23:111-18.
5. Fabris P, Baldo V, Baldovin T, et al. A. Changing epidemiology of HCV and HBV infections in Northern Italy: a survey in the general population. J Clin Gastroenterol 2008; 42:527-32.
6. Palumbo E, Scotto G, Faleo G, et al. Prevalence of HBV-genotypes in immigrants affected by HBV-related chronic active hepatitis. Arq Gastroenterol 2007; 44:54-7.
7. Stroffolini T, Almasio PL, Sagnelli E, et al. Evolving clinical landscape of chronic hepatitis B: A multicenter Italian study. J Med Virol 2009; 81:1999-2006.
8. Di Marco V, Lo Iacono O, Cammà C, et al. The long-term course of chronic hepatitis B. Hepatology 1999; 30:257-64.
9. Fattovich G. Natural history and prognosis of hepatitis B. Semin Liver Dis 2003; 23:47-58.
10. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008; 48:335-352.
11. Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130;678-86.
12. Chen C-J, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006; 295:65-73.
13. Chen YC, Sheen IS, Chu CM, et al. Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology 2002; 123:1084-9.
14. Mommeja-Marin H, Mondou E, Blum MR, et al. Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. Hepatology 2003; 37:1309-19.
15. Zoulim F. Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection. Antiv Res 2004; 64:1-15.
16. Chang TT, Liaw YF, Wu SS, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010; 52:886-93.
17. Hadziyannis S, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131: 1743-51.
18. Liaw YF, Chien RN, Yeh CT. No benefit to continue lamivudine therapy after emergence of YMDD mutations. Antivir Ther 2004; 9:257-62.
19. Yuen MF, Kato T, Mizokami M, et al. Clinical outcome and virologic profiles of severe hepatitis B exacerbation due to YMDD mutations. J Hepatol 2003; 39:850-5.
20. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. NEJM 2004; 351:1221-1231.
21. Di Marco V, Marzano A, Lampertico P, et al. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology 2004; 40:883-91.
22. Fattovich G, Giustina G, Sanchez-Tapias J, et al. Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. Am J Gastroenterol 1998; 93:896-900.
23. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of chronic hepatitis B. J Hepatol 2009; 50:227-42.
24. Carosi G, Rizzetto M, Alberti A, et al. Treatment of chronic hepatitis B: Update of the recommendations from the 2007 Italian Workshop. Dig Liver Dis 2011 in press.
25. Colombo GL, Gaeta GB, Viganò M, et al. A cost-effectiveness analysis of different therapies in patients with chronic hepatitis B in Italy. ClinicoEconomics and Outcomes Research 2011; 3:37-46.
26. Buti M, Brosa M, Casado MA, et al. Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B. J Hepatol 2009; 51:640-6.
27. Woo G, Tomlinson G, Nishikawa Y, et al. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology 2010; 139:1218-29.
28. Dakin H, Bentley A, Dusheiko G. Cost-utility analysis of tenofovir disoproxil fumarate in the treatment of chronic hepatitis B. Value Health. 2010; 13:922-33.